You Position: Home > Paper

Minimal residual disease-directed individualized therapy for hematological malignancies

( views:0, downloads:0 )
Author:
No author available
Journal Title:
Journal of Leukemia and Lymphoma
Issue:
1
DOI:
10.3760/cma.j.cn115356-20221230-00366
Key Word:
恶性血液病;白血病,髓样,急性;微小残留病;异基因造血干细胞移植;分子靶向治疗;Hematological malignancies;Leukemia, myeloid, acute;Minimal residual disease;Allogneic hematopoietic stem cell transplantation;Molecular targeted ther

Abstract´╝Ü Minimal residual disease (MRD) has been used for warning of relapse and guiding the therapy selection for hematological malignancies including acute leukemia. Based on MRD-related content reported at the 64th American Society of Hematology (ASH) Annual Meeting, this article discusses the progress of MRD-directed individualized therapy for hematological malignancies with a primary focus on acute myeloid leukemia.

  • This article has no references!
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn